{"success":true,"data":{"pressRelease":{"id":"167439","rtpr_id":"nBw1vhL55a-20261013","ticker":"ATRC","exchange":"NASDAQ","all_tickers":["ATRC"],"title":"AtriCure to Announce Third Quarter 2026 Financial Results","author":"Business Wire","published_at":"2026-10-13T12:00:01.238Z","article_body":"AtriCure to Announce Third Quarter 2026 Financial Results\n\nAtriCure, Inc.\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fprotect.checkpoint.com%2Fv2%2Fr01%2F___http%3A%2Fwww.Atricure.com___.YzJ1OmdpbG1hcnRpbmdyb3VwOmM6b2ZmaWNlMzY1X2VtYWlsc19hdHRhY2htZW50OjEwMGNiYWRiNDFiZTg0NTM0YmM1NDhlYmYyNjI1NzAzOjc6MzcyMTplNzIxNzFlYWM5MWJlMWFkZWE2N2ZmMWRmZTlkNGEwYzQ2YjA5YWQzMjg3MDU5MzFlZDlhZmJmYTk4MDk2NGY0OnA6RjpG&esheet=54617720&newsitemid=20261013083843&lan=en-US&anchor=AtriCure%2C+Inc.&index=1&md5=02b6410845e201a9b73131caf93ab64c)\n(Nasdaq: ATRC\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fprotect.checkpoint.com%2Fv2%2Fr01%2F___http%3A%2Fir.atricure.com%2Fphoenix.zhtml%3Fc%3D189981%26p%3Dirol-irhome___.YzJ1OmdpbG1hcnRpbmdyb3VwOmM6b2ZmaWNlMzY1X2VtYWlsc19hdHRhY2htZW50OjEwMGNiYWRiNDFiZTg0NTM0YmM1NDhlYmYyNjI1NzAzOjc6MGJhYTpjOWZiZTgxZTMxMTFkNjMzNTk0MDQ4OGRhMTU3NWZhNGU5MTE4YzNhOTQzYzE1ZDYzNDFhNDdkNjJmOTU4NTM3OnA6RjpG&esheet=54617720&newsitemid=20261013083843&lan=en-US&anchor=Nasdaq%3A+ATRC&index=2&md5=c30d2937944ea191547c179ebfba3e50)\n), a leading innovator in surgical treatments and therapies for atrial\nfibrillation (Afib), left atrial appendage (LAA) management, and\npost-operative pain management, today announced that it will release its third\nquarter 2026 financial results on Tuesday, November 3, 2026.\n\nAtriCure will host an audio webcast at 4:30 p.m. Eastern Time on Tuesday,\nNovember 3, 2026, to discuss its third quarter financial results. Those\ninterested in listening to the conference call should register online using\nthis link\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fprotect.checkpoint.com%2Fv2%2Fr01%2F___https%3A%2Fedge.media-server.com%2Fmmc%2Fp%2F3rs56u9i___.YzJ1OmdpbG1hcnRpbmdyb3VwOmM6b2ZmaWNlMzY1X2VtYWlsc19hdHRhY2htZW50OjEwMGNiYWRiNDFiZTg0NTM0YmM1NDhlYmYyNjI1NzAzOjc6NWIwYzo0MzVjOTgwMTE1NDZhMmRmZjY3MDY1ODBhOTBiNmE4OTE5ZjA5Y2RlNzZmMWZhOTgwN2ZlNzJhZWVkNGJlNzNjOnA6RjpG&esheet=54617720&newsitemid=20261013083843&lan=en-US&anchor=register+online+using+this+link&index=3&md5=630fa093ba3f5be6cac4d665d7b6361b)\n. Participants are encouraged to register more than 15 minutes before the\nstart of the call. A live and replay version of the audio webcast will be\navailable at https://ir.atricure.com/events-and-presentations/events\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fprotect.checkpoint.com%2Fv2%2Fr01%2F___https%3A%2Fnam12.safelinks.protection.outlook.com%2F%3Furl%3Dhttps%253A%252F%252Fir.atricure.com%252Fevents-and-presentations%252Fevents%26data%3D05%257C01%257CADoerger%2540atricure.com%257C2e4c9d52f16b4e13d2c908dafa305bd2%257C95b31e49550f49b385bcf6d234756d30%257C0%257C0%257C638097382893887257%257CUnknown%257CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%253D%257C7000%257C%257C%257C%26sdata%3Dcg3q%252BadxnsOPsBQ%252FMpEH0GB08UY9hO48IKSHy%252BFkIZY%253D%26reserved%3D0___.YzJ1OmdpbG1hcnRpbmdyb3VwOmM6b2ZmaWNlMzY1X2VtYWlsc19hdHRhY2htZW50OjEwMGNiYWRiNDFiZTg0NTM0YmM1NDhlYmYyNjI1NzAzOjc6NWI2YzoyZGMwNzBhMDI4NGNiODBmYjU0NGEzNDE5NmJiYzBhZmY0MWE1ZDQwYTVmNjkxMzUwZTU1NWJmNzI0NDUyZjkwOnA6RjpG&esheet=54617720&newsitemid=20261013083843&lan=en-US&anchor=https%3A%2F%2Fir.atricure.com%2Fevents-and-presentations%2Fevents&index=4&md5=26ee078ba0ea4525f8a4697649fdf3d2)\n.\n\nAbout AtriCure\n\nAtriCure, Inc. provides innovative technologies for the treatment of Afib and\nrelated conditions. Afib affects more than 59 million people worldwide.\nSurgeons around the globe use AtriCure technologies for the treatment of Afib,\nreduction of Afib related complications and post-operative pain management.\nAtriCure’s Isolator® Synergy™ Ablation System is the first medical device\nto receive FDA approval for the treatment of persistent Afib. AtriCure’s\nAtriClip® Left Atrial Appendage Exclusion System products are the most widely\nsold LAA management devices worldwide. AtriCure’s Hybrid AF™ Therapy is a\nminimally invasive procedure that provides a lasting solution for\nlong-standing persistent Afib patients. AtriCure’s cryoICE cryoSPHERE® and\ncryoXT® probes are cleared for temporary ablation of peripheral nerves to\nblock pain, providing pain relief in cardiac, thoracic and amputation\nprocedures. For more information, visit AtriCure.com\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.AtriCure.com&esheet=54617720&newsitemid=20261013083843&lan=en-US&anchor=AtriCure.com&index=5&md5=0a8ee30bb1f35abafa050e57ab665710)\nor follow us on X @AtriCure.\n\n\n\nView source version on businesswire.com:\nhttps://www.businesswire.com/news/home/20261013083843/en/\n(https://www.businesswire.com/news/home/20261013083843/en/)\n\nAngie Wirick\n\nAtriCure, Inc.\n\nChief Financial Officer\n\n(513) 755-5334\n\nawirick@atricure.com (mailto:awirick@atricure.com)\n\nMarissa Bych\n\nGilmartin Group\n\nInvestor Relations\n\nmarissa@gilmartinir.com (mailto:marissa@gilmartinir.com)\n\n\nCopyright Business Wire 2026","article_body_html":"","raw_payload":{"data":{"id":"nBw1vhL55a-20261013","title":"AtriCure to Announce Third Quarter 2026 Financial Results","author":"Business Wire","ticker":"ATRC","created":"2026-10-13T12:00:01.238Z","tickers":["ATRC"],"exchange":"NASDAQ","article_body":"AtriCure to Announce Third Quarter 2026 Financial Results\n\nAtriCure, Inc.\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fprotect.checkpoint.com%2Fv2%2Fr01%2F___http%3A%2Fwww.Atricure.com___.YzJ1OmdpbG1hcnRpbmdyb3VwOmM6b2ZmaWNlMzY1X2VtYWlsc19hdHRhY2htZW50OjEwMGNiYWRiNDFiZTg0NTM0YmM1NDhlYmYyNjI1NzAzOjc6MzcyMTplNzIxNzFlYWM5MWJlMWFkZWE2N2ZmMWRmZTlkNGEwYzQ2YjA5YWQzMjg3MDU5MzFlZDlhZmJmYTk4MDk2NGY0OnA6RjpG&esheet=54617720&newsitemid=20261013083843&lan=en-US&anchor=AtriCure%2C+Inc.&index=1&md5=02b6410845e201a9b73131caf93ab64c)\n(Nasdaq: ATRC\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fprotect.checkpoint.com%2Fv2%2Fr01%2F___http%3A%2Fir.atricure.com%2Fphoenix.zhtml%3Fc%3D189981%26p%3Dirol-irhome___.YzJ1OmdpbG1hcnRpbmdyb3VwOmM6b2ZmaWNlMzY1X2VtYWlsc19hdHRhY2htZW50OjEwMGNiYWRiNDFiZTg0NTM0YmM1NDhlYmYyNjI1NzAzOjc6MGJhYTpjOWZiZTgxZTMxMTFkNjMzNTk0MDQ4OGRhMTU3NWZhNGU5MTE4YzNhOTQzYzE1ZDYzNDFhNDdkNjJmOTU4NTM3OnA6RjpG&esheet=54617720&newsitemid=20261013083843&lan=en-US&anchor=Nasdaq%3A+ATRC&index=2&md5=c30d2937944ea191547c179ebfba3e50)\n), a leading innovator in surgical treatments and therapies for atrial\nfibrillation (Afib), left atrial appendage (LAA) management, and\npost-operative pain management, today announced that it will release its third\nquarter 2026 financial results on Tuesday, November 3, 2026.\n\nAtriCure will host an audio webcast at 4:30 p.m. Eastern Time on Tuesday,\nNovember 3, 2026, to discuss its third quarter financial results. Those\ninterested in listening to the conference call should register online using\nthis link\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fprotect.checkpoint.com%2Fv2%2Fr01%2F___https%3A%2Fedge.media-server.com%2Fmmc%2Fp%2F3rs56u9i___.YzJ1OmdpbG1hcnRpbmdyb3VwOmM6b2ZmaWNlMzY1X2VtYWlsc19hdHRhY2htZW50OjEwMGNiYWRiNDFiZTg0NTM0YmM1NDhlYmYyNjI1NzAzOjc6NWIwYzo0MzVjOTgwMTE1NDZhMmRmZjY3MDY1ODBhOTBiNmE4OTE5ZjA5Y2RlNzZmMWZhOTgwN2ZlNzJhZWVkNGJlNzNjOnA6RjpG&esheet=54617720&newsitemid=20261013083843&lan=en-US&anchor=register+online+using+this+link&index=3&md5=630fa093ba3f5be6cac4d665d7b6361b)\n. Participants are encouraged to register more than 15 minutes before the\nstart of the call. A live and replay version of the audio webcast will be\navailable at https://ir.atricure.com/events-and-presentations/events\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fprotect.checkpoint.com%2Fv2%2Fr01%2F___https%3A%2Fnam12.safelinks.protection.outlook.com%2F%3Furl%3Dhttps%253A%252F%252Fir.atricure.com%252Fevents-and-presentations%252Fevents%26data%3D05%257C01%257CADoerger%2540atricure.com%257C2e4c9d52f16b4e13d2c908dafa305bd2%257C95b31e49550f49b385bcf6d234756d30%257C0%257C0%257C638097382893887257%257CUnknown%257CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%253D%257C7000%257C%257C%257C%26sdata%3Dcg3q%252BadxnsOPsBQ%252FMpEH0GB08UY9hO48IKSHy%252BFkIZY%253D%26reserved%3D0___.YzJ1OmdpbG1hcnRpbmdyb3VwOmM6b2ZmaWNlMzY1X2VtYWlsc19hdHRhY2htZW50OjEwMGNiYWRiNDFiZTg0NTM0YmM1NDhlYmYyNjI1NzAzOjc6NWI2YzoyZGMwNzBhMDI4NGNiODBmYjU0NGEzNDE5NmJiYzBhZmY0MWE1ZDQwYTVmNjkxMzUwZTU1NWJmNzI0NDUyZjkwOnA6RjpG&esheet=54617720&newsitemid=20261013083843&lan=en-US&anchor=https%3A%2F%2Fir.atricure.com%2Fevents-and-presentations%2Fevents&index=4&md5=26ee078ba0ea4525f8a4697649fdf3d2)\n.\n\nAbout AtriCure\n\nAtriCure, Inc. provides innovative technologies for the treatment of Afib and\nrelated conditions. Afib affects more than 59 million people worldwide.\nSurgeons around the globe use AtriCure technologies for the treatment of Afib,\nreduction of Afib related complications and post-operative pain management.\nAtriCure’s Isolator® Synergy™ Ablation System is the first medical device\nto receive FDA approval for the treatment of persistent Afib. AtriCure’s\nAtriClip® Left Atrial Appendage Exclusion System products are the most widely\nsold LAA management devices worldwide. AtriCure’s Hybrid AF™ Therapy is a\nminimally invasive procedure that provides a lasting solution for\nlong-standing persistent Afib patients. AtriCure’s cryoICE cryoSPHERE® and\ncryoXT® probes are cleared for temporary ablation of peripheral nerves to\nblock pain, providing pain relief in cardiac, thoracic and amputation\nprocedures. For more information, visit AtriCure.com\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.AtriCure.com&esheet=54617720&newsitemid=20261013083843&lan=en-US&anchor=AtriCure.com&index=5&md5=0a8ee30bb1f35abafa050e57ab665710)\nor follow us on X @AtriCure.\n\n\n\nView source version on businesswire.com:\nhttps://www.businesswire.com/news/home/20261013083843/en/\n(https://www.businesswire.com/news/home/20261013083843/en/)\n\nAngie Wirick\n\nAtriCure, Inc.\n\nChief Financial Officer\n\n(513) 755-5334\n\nawirick@atricure.com (mailto:awirick@atricure.com)\n\nMarissa Bych\n\nGilmartin Group\n\nInvestor Relations\n\nmarissa@gilmartinir.com (mailto:marissa@gilmartinir.com)\n\n\nCopyright Business Wire 2026"},"type":"article","timestamp":"2026-10-13T12:00:01.679865206Z","server_sent_at_ms":1791892801679},"received_at":"2026-10-13T12:00:01.731Z","source_url":"https://www.businesswire.com/news/home/20261013083843/en/"},"analysis":{"id":"155741","press_release_id":"167439","analysis_json":{"industry":{"label":"Health Care Equipment & Supplies","sector":"Health Care"},"redFlags":[],"eventType":"other","narrative":"AtriCure announced it will release third quarter 2026 financial results on Tuesday, November 3, 2026.\n\nThe company will host an audio webcast at 4:30 p.m. Eastern Time that day, with registration recommended at least 15 minutes before the call; a replay will be available on its investor relations site.\n\nThis is a scheduling notice only and contains no financial results or guidance.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Calendar item: AtriCure Q3 2026 results and webcast on November 3, 2026."},"keyFigures":{},"namedEntities":{"people":[{"name":"Angie Wirick","role":"Chief Financial Officer"},{"name":"Marissa Bych","role":"Investor Relations, Gilmartin Group"}],"products":["Isolator Synergy Ablation System","AtriClip Left Atrial Appendage Exclusion System","Hybrid AF Therapy","cryoICE cryoSPHERE","cryoXT"],"companies":[{"name":"AtriCure, Inc.","ticker":"ATRC","relationship":"issuer"},{"name":"Gilmartin Group","relationship":"investor relations firm"}],"dollarAmounts":[]},"materialImpact":{"score":1,"reasoning":"This is an earnings-date and conference-call scheduling notice with no results, figures, or guidance. Boilerplate announcement only."},"tickerRelevance":{"others":[],"primary":"ATRC"},"globalImportance":10,"audienceRelevance":15,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"mid-cap medtech","eventGravity":"earnings-date-notice","resultsIncluded":false}},"event_type":"other","event_type_secondary":null,"sentiment":"neutral","material_impact_score":1,"narrative":"AtriCure announced it will release third quarter 2026 financial results on Tuesday, November 3, 2026.\n\nThe company will host an audio webcast at 4:30 p.m. Eastern Time that day, with registration recommended at least 15 minutes before the call; a replay will be available on its investor relations site.\n\nThis is a scheduling notice only and contains no financial results or guidance.","key_figures":{},"named_entities":{"people":[{"name":"Angie Wirick","role":"Chief Financial Officer"},{"name":"Marissa Bych","role":"Investor Relations, Gilmartin Group"}],"products":["Isolator Synergy Ablation System","AtriClip Left Atrial Appendage Exclusion System","Hybrid AF Therapy","cryoICE cryoSPHERE","cryoXT"],"companies":[{"name":"AtriCure, Inc.","ticker":"ATRC","relationship":"issuer"},{"name":"Gilmartin Group","relationship":"investor relations firm"}],"dollarAmounts":[]},"model_name":"glm-5.3-flashx","prompt_hash":"sha256:5c812bd9e28b810d","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-10-13T12:00:18.636Z","global_importance":10,"audience_relevance":15,"importance_components":{"tickerTier":"mid-cap medtech","eventGravity":"earnings-date-notice","resultsIncluded":false}},"durationMs":4361,"modelName":"glm-5.3-flashx"}}